Shots:
- Alfasigma has entered into an agreement with SEVER Life Sciences to acquire 100% of Nordic Pharma & its subsidiaries, adding the Nordimet methotrexate franchise to Alfasigma’s rheumatology portfolio alongside Jyseleca
- Deal will expand Alfasigma’s commercial footprint through Nordic Pharma’s direct operations across 18 EU countries, while adding platforms in Canada & Japan. The portfolio also incl. women’s health, critical care & ophthalmology products
- Acquisition will bring 265 employees with specialized expertise & supports Alfasigma’s M&A-led international growth strategy across specialty & rare diseases
Ref: Globenewswire | Image: Nordic Pharma | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
